| 2.80 Delayed Data As of 11:25am ET |  +0.07 / +2.56%Today’s Change | 1.03 Today|||52-Week Range 7.61 | +8.53% Year-to-Date |
| Jazz's (JAZZ) New Sleep Drug Sunosi Gets Schedule IV Status 10:22am / Zacks.comZAK - Paid Partner Content | Avadel Pharmaceuticals Appoints Gregory J. Divis Chief Executive Officer Jun 03 / GlobeNewswirePNW - Paid Partner Content |
| Avadel to Present New Data on Once-Nightly Sodium Oxybate at SLEEP 2019 Conference Jun 04 / GlobeNewswirePNW - Paid Partner Content | Avadel Pharmaceuticals Announces FDA Acceptance of New Drug Application for AV001 May 22 / GlobeNewswirePNW - Paid Partner Content |
| Previous close | 2.73 |
| Today’s open | 2.76 |
| Day’s range | 2.70 - 2.98 |
| Volume | 226,772 |
| Average volume (3 months) | 266,203 |
| Market cap | $118.4M |
| Earnings growth (last year) | -249.68% |
| Earnings growth (this year) | +36.68% |
| Earnings growth (next 5 years) | +13.00% |
| Revenue growth (last year) | -40.94% |
| P/E ratio | NM |
| Price/Sales | 0.93 |
| Price/Book | 42.55 |
| Today’s change | Today’s % change | |
|---|---|---|
| MDWDMediwound Ltd | -0.15 | -4.01% |
| TRVNTrevena Inc | 0.00 | 0.00% |
| ABUSArbutus Biopharma Co... | -0.05 | -2.75% |
| CEMIChembio Diagnostics ... | 0.00 | 0.00% |
| Next reporting date | August 6, 2019 |
| EPS forecast (this quarter) | -$0.33 |
| Annual revenue (last year) | $103.2M |
| Annual profit (last year) | -$95.2M |
| Net profit margin | -92.29% |
Sector Health Technology |
Industry Medical Specialties |
Chief Executive Officer & Director Gregory J. Divis |
Chief Financial Officer & Senior Vice President Michael F. Kanan |
Corporate headquarters Dublin, Dublin |
